Replies to post #134443 on Biotech Values

[DewDiligence]

CCXI (ChemoCentryx) IPO’s at $10/sh:

http://www.reuters.com/article/2012/02/08/chemocentryx-idUSL4E8D877F20120208

The original has been an IPO in the $14-16 range. GSK is a CCXI shareholder and also a licensee (#msg-70579127).

[mcbio]

CCXI

GSK licenses phase-2 RA drug from private company, ChemoCentryx:

finance.yahoo.com/news/GSK-Exercises-Option-License-prnews-3466860868.html?x=0
Quote:
CCX354 is a potent and selective antagonist of CCR1, a chemokine receptor that drives the recruitment of certain inflammatory cells including populations of monocytes, macrophages and T cells into the joints of patients with RA. By selectively blocking the CCR1 receptor, CCX354 is designed to reduce the infiltration of inflammatory cells into the joints of RA patients, thus inhibiting the inflammation, swelling, pain and associated joint destruction while minimizing the potential for off-target effects.

Are you aware of any updates from GSK on this RA program? Just curious if GSK is still pushing forward here and wonder about where an oral CCR1 inhibitor fits into the RA landscape given the emergence of the JAK class. Is there an opportunity here?

Here's a link to the prior Phase 2 data for this drug: http://ir.chemocentryx.com/releasedetail.cfm?ReleaseID=643829 .